Home › Emmaus Life Sciences To Present Phase 3 Sickle Cell Disease Clinical Trial Data
 

Keywords :   


Emmaus Life Sciences To Present Phase 3 Sickle Cell Disease Clinical Trial Data

2015-04-01 07:37:14| drugdiscoveryonline Home Page

Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases recently announced that data from the Company’s Phase 3 clinical trial of its pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell anemia and sickle beta-0 thalassemia, will be presented, during the 9th Annual Sickle Cell Disease Research and Educational Symposium and 38th National Sickle Cell Disease Scientific Meeting

Tags: data life present cell

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.05P&G Patents Hair Conditioner with Antimicrobial System
03.05Post Offices expert gave false evidence to court
03.05Melting Massage Bar Patented by Johnson & Johnson
03.05How the computer games industry is embracing AI
03.05Apple sees biggest fall in sales for a year
02.05Turkey halts trade with Israel over Gaza 'tragedy'
02.05Loop Industries and Ester Ltd. Announce Joint Venture
02.05The Oldham Group names Hunter Collins account manager
More »